Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.

Future oncology (London, England)

Volumn 9, Issue 12, 2013, Pages 1829-1839

  Barth, Matthew J ^a   Czuczman, Myron S ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIGEN; DRUG DERIVATIVE; FLUDARABINE; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB; VIDARABINE;

ANIMAL; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; IMMUNOLOGY; MOUSE; PATHOLOGY; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; NEOPLASM RECURRENCE, LOCAL; VIDARABINE;

EID: 84899686547     PISSN: None     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.219     Document Type: Article

References (0)